Research summary
Tesofensine
A small molecule that inhibits dopamine, norepinephrine, and serotonin transporters. Phase 2 trials studied appetite and weight outcomes. It is not FDA-approved.
Monoamine Transporter Research CompoundSmall-molecule phenyltropane derivativeMW≈259.8 g/mol (free base)CAS195875-84-4NCAAUnclear
Evidence at a glance
What the research says about Tesofensine
The Tesofensine evidence base cited here is 4 sources — 4 clinical. Its strongest evidence is human — 4 clinical studies, most recently 2013 ("Dopamine, norepinephrine, and serotonin transporter occupancy by tesofen…").
Key findings
What the literature shows
- Tesofensine inhibits dopamine, norepinephrine, and serotonin transporters. Human PET data and pharmacology studies support this triple monoamine reuptake mechanism.
- A randomized phase 2 trial studied weight change in adults with obesity. This is clinical research evidence. It is not an FDA approval.
- The trial reported adverse events that included dry mouth, nausea, constipation, insomnia, and increased heart rate.
Citations
4 peer-reviewed sources
All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.
Related research